Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v5-FR Version v5-FR
Language French French
Date Updated 2025-05-02 2025-05-02
Drug Identification Number 02204266 02204266
Brand name DEXAMETHASONE-OMEGA DEXAMETHASONE-OMEGA
Common or Proper name DEXAMETHASONE PHOSPHATE INJECTION DEXAMETHASONE PHOSPHATE INJECTION
Company Name OMEGA LABORATORIES LIMITED OMEGA LABORATORIES LIMITED
Ingredients DEXAMETHASONE PHOSPHATE DEXAMETHASONE PHOSPHATE
Strength(s) 4MG 4MG
Dosage form(s) LIQUID LIQUID
Route of administration SOFT TISSUE INJECTION INTRAVENOUS INTRAMUSCULAR INTRALESIONAL INTRA-ARTICULAR SOFT TISSUE INJECTION INTRAVENOUS INTRAMUSCULAR INTRALESIONAL INTRA-ARTICULAR SOFT TISSUE INJECTION INTRAVENOUS INTRAMUSCULAR INTRALESIONAL INTRA-ARTICULAR SOFT TISSUE INJECTION INTRAVENOUS INTRAMUSCULAR INTRALESIONAL INTRA-ARTICULAR
Packaging sizes (GTIN) (See additional packaging sizes) (See additional packaging sizes)
Additional packaging sizes 10 X 25 mL vial / fiole 10 X 25 mL vial / fiole
ATC code H02AB H02AB
ATC description CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date 2025-07-01 2025-07-01
Actual start date
Estimated end date 2025-07-31 2025-07-31
Actual end date
Shortage status Anticipated shortage Anticipated shortage
Tier 3 Status No No
Company comments We are currently collaborating with Health Canada’s Drug Shortages Unit to mitigate any market impact. We are currently collaborating with Health Canada’s Drug Shortages Unit to mitigate any market impact.
Health Canada comments